Seeking Alpha

Nektar Therapeutics (NKTR +0.8%) is a beneficiary of the FDA's approval of Affymax's (AFFY...

Nektar Therapeutics (NKTR +0.8%) is a beneficiary of the FDA's approval of Affymax's (AFFY +35.4%) peginesatide treatment of anemia in dialysis patients. Nektar has an exclusive agreement under which it will provide Affymax with its proprietary technology for use in the drug's manufacture in exchange for manufacturing revenue, milestone and other payments.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs